Last C$1.01 CAD
Change Today +0.02 / 2.02%
Volume 21.0K
As of 3:43 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

adherex technologies inc (AHX) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/27/14 - C$2.59
52 Week Low
09/12/13 - C$0.21
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

adherex technologies inc (AHX) Related Businessweek News

No Related Businessweek News Found

adherex technologies inc (AHX) Details

Adherex Technologies Inc., together with its subsidiaries, operates as a development stage biopharmaceutical company with a portfolio of product candidates under development for use in the treatment of cancer. Its lead product candidates include Sodium Thiosulfate, a water soluble thiol compound, which is in phase III clinical trials that act as a chemical reducing agent for the prevention of cisplatin induced hearing loss or ototoxicity in children; and Eniluracil, an oral irreversible dihydropyrimidine dehydrogenase inhibitor for the rapid break down of 5-FU in the body, which has completed phase II clinical trials for the treatment of metastatic breast cancer. Adherex Technologies Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

1 Employees
Last Reported Date: 05/14/14
Founded in 1996

adherex technologies inc (AHX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $140.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $26.5K
Total Annual Compensation: $71.5K
Compensation as of Fiscal Year 2013.

adherex technologies inc (AHX) Key Developments

Adherex Technologies Inc. Announces Results from Two Sodium Thiosulfate Phase 3 Studies

Adherex Technologies Inc. announced the results on the two Sodium Thiosulfate (STS) Phase III studies presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. COG Study ACCL0431, "A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children," finished enrollment of 131 patients in first quarter 2012. The patients had been previously diagnosed with childhood cancers. The primary endpoint was to evaluate the efficacy of STS for prevention of hearing loss in children receiving cisplatin chemotherapy (hypothesis: 50% relative reduction in hearing loss). Secondary endpoints included: Compare change in mean hearing thresholds, Compare incidence of other Grade 3/4 toxicities (renal and hematological) and Monitor Event Free Survival (EFS) and Overall Survival (OS) in two groups. Preliminary Results: 126 eligible subjects were enrolled with germ cell tumor (32), osteosarcoma (30), neuroblastoma (26), medulloblastoma (26), hepatoblastoma (7) or other (5). Of these 104 subjects (64 male and 29 <5 years old) were evaluable for the primary endpoint. Subjects were randomized either to no treatment (control) or treatment with STS 16 grams/m2 IV over 15 minutes 6 hours after each cisplatin dose. Hearing was measured using standard audiometry for age and data were reviewed centrally using American Speech-Language-Hearing Association criteria. The proportion of subjects with hearing loss assessed at 4 weeks post the final cisplatin dose (primary endpoint) and EFS/OS (log-rank test, 2-year cumulative estimates and Cox proportional hazards model) were compared between the two groups. The proportion of hearing loss for STS vs. Control was 28.6% (14/49) vs.56.4% (31/55), respectively (p=0.004). Including all 126 subjects at median post-enrollment follow-up of 2.9 years for censored patients, EFS for STS vs. Control was 61.2% vs. 69.9% (p=0.31); OS was 77.0% vs. 88.9% (p=0.029). A subset analysis by extent of disease determined post hoc was performed: For subjects with localized disease, EFS for STS (N=40) vs. Control (N=38) was 72.5% vs. 68.3% (p=0.94); HR (hazard ratio) 1.03 (p=0.94); OS was 89.0% vs. 89.5% (p=0.48); HR 1.58 (p=0.48). For those with disseminated (metastatic) disease, EFS for STS (N=21) vs. Control (N=26) was 41.6% vs. 72.5% (p=0.085); HR 2.13 (p=0.092); OS was 55.9% vs. 88.1% (p=0.011); HR 3.97 (p=0.019). Preliminary Conclusions: STS protects against cisplatin-induced hearing loss in children, especially for those < 5 years old. In this study, use of STS did not result in lower EFS/OS in patients with localized disease. However, the lower survival among those with disseminated disease raises the concern of a tumor protective effect when STS is administered on this dose and schedule. The primary objectives of the study are: to assess the efficacy of STS to reduce the hearing impairment caused by cisplatin and to carefully monitor any potential impact of STS on response to cisplatin and survival. The primary endpoint of the study is centrally reviewed absolute hearing threshold, at the age of >=3.5 yrs, by pure tone audiometry, graded by Brock criteria.

Adherex Technologies Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Adherex Technologies announced unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported net loss and comprehensive loss of $3,194,000 or $0.11 per basic and diluted share against $4,108,000 or $0.16 per basic and diluted share a year ago. Loss from operations was $537,000 against $537,000 a year ago.

Adherex Technologies Inc., Annual General Meeting, May 28, 2014

Adherex Technologies Inc., Annual General Meeting, May 28, 2014., at 15:00 US Eastern Standard Time. Location: Quintiles Plaza, 4820 Emperor Boulevard. Agenda: To receive the consolidated financial statements for the year ended December 31, 2013, together with the report of the auditors thereon; to elect directors; to appoint auditors and to authorize the directors to fix the auditors' remuneration; to vote on an advisory vote on executive compensation; to consider and, if deemed advisable, pass a special resolution in the form set out in Schedule "B" to the Management Proxy Circular approving the exchange of common share purchase warrants; to consider and, if deemed advisable, pass a special resolution in the form set out in Schedule "C" to the Management Proxy Circular approving an alteration of the company’s name; to consider and, if deemed advisable, pass a special resolution in the form set out in Schedule "D" to the Management Proxy Circular approving a consolidation of the company’s outstanding common shares; and to transact such further or other business as may properly come before the Meeting or any adjournment thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AHX:CN C$1.01 CAD +0.02

AHX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AHX.
View Industry Companies

Industry Analysis


Industry Average

Valuation AHX Industry Range
Price/Earnings 11.1x
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow 9.9x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADHEREX TECHNOLOGIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at